Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Page 1
Incidental Carcinoid Tumor of the Appendix After Appendectomy During Pregnancy.
Smester Lopez JA, Garcia JA, Lopez E, Gonzalez JA, Calzado Capobianco M. Smester Lopez JA, et al. Among authors: garcia ja. Cureus. 2023 Nov 9;15(11):e48561. doi: 10.7759/cureus.48561. eCollection 2023 Nov. Cureus. 2023. PMID: 38073928 Free PMC article.
The patient had a successful recovery and was discharged home a week after surgery. She gave birth to a full-term, healthy baby and remains free of tumor relapse. ...
The patient had a successful recovery and was discharged home a week after surgery. She gave birth to a full-term, healthy bab …
Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer.
Jones RH, Fizazi K, James ND, Tammela TL, Matsubara N, Priou F, Beuzeboc P, Lesimple T, Bono P, Kataja V, Garcia JA, Protheroe A, Shore N, Aspegren J, Joensuu H, Kuss I, Fiala-Buskies S, Vjaters E. Jones RH, et al. Among authors: garcia ja. Prostate Cancer Prostatic Dis. 2023 Oct 26. doi: 10.1038/s41391-023-00740-9. Online ahead of print. Prostate Cancer Prostatic Dis. 2023. PMID: 37884613
All treatment-related TEAEs (n = 5) were grade 1. CONCLUSIONS: Long-term darolutamide treatment was well tolerated; no new safety signals observed. In patients with mCRPC, long-term darolutamide treatment was well tolerated and no new safety signals were observed. . …
All treatment-related TEAEs (n = 5) were grade 1. CONCLUSIONS: Long-term darolutamide treatment was well tolerated; no new safety sig …
Immune Checkpoint Inhibitors and Long-term Survival of Patients With Metastatic Urothelial Cancer.
Zhu A, Garcia JA, Faltas B, Grivas P, Barata P, Shoag JE. Zhu A, et al. Among authors: garcia ja. JAMA Netw Open. 2023 Apr 3;6(4):e237444. doi: 10.1001/jamanetworkopen.2023.7444. JAMA Netw Open. 2023. PMID: 37043205 Free PMC article.
This cohort study uses published clinical trial data to assess long-term survival of patients with metastatic urothelial carcinoma who are treated with immune checkpoint inhibitors....
This cohort study uses published clinical trial data to assess long-term survival of patients with metastatic urothelial carcinoma wh …
Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort.
Kirk PS, Lotan Y, Zargar H, Fairey AS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobson NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Aning J, Shariat SF, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Grivas P, Garcia JA, Stephenson AJ, Shah JB, Daneshmand S, Spiess PE, van Rhijn BWG, Mertens L, Black P, Wright JL. Kirk PS, et al. Among authors: garcia ja. J Urol. 2023 May;209(5):882-889. doi: 10.1097/JU.0000000000003193. Epub 2023 Feb 16. J Urol. 2023. PMID: 36795962
CONCLUSIONS: In patients undergoing transurethral resection for muscle-invasive bladder cancer prior to neoadjuvant chemotherapy, maximal resection may improve pathological response at cystectomy. However, the ultimate effects on long-term survival and oncologic outcomes w …
CONCLUSIONS: In patients undergoing transurethral resection for muscle-invasive bladder cancer prior to neoadjuvant chemotherapy, maximal re …
Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials.
Ma TM, Sun Y, Malone S, Roach M 3rd, Dearnaley D, Pisansky TM, Feng FY, Sandler HM, Efstathiou JA, Syndikus I, Hall EC, Tree AC, Sydes MR, Cruickshank C, Roy S, Bolla M, Maingon P, De Reijke T, Nabid A, Carrier N, Souhami L, Zapatero A, Guerrero A, Alvarez A, Gonzalez San-Segundo C, Maldonado X, Romero T, Steinberg ML, Valle LF, Rettig MB, Nickols NG, Shoag JE, Reiter RE, Zaorsky NG, Jia AY, Garcia JA, Spratt DE, Kishan AU; Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators. Ma TM, et al. Among authors: garcia ja. J Clin Oncol. 2023 Feb 1;41(4):881-892. doi: 10.1200/JCO.22.00970. Epub 2022 Oct 21. J Clin Oncol. 2023. PMID: 36269935 Free PMC article.
MATERIALS AND METHODS: Individual patient data from 12 randomized trials that included patients receiving neoadjuvant/concurrent or concurrent/adjuvant short-term ADT (4-6 months) with RT for localized disease were obtained from the Meta-Analysis of Randomized trials in Ca …
MATERIALS AND METHODS: Individual patient data from 12 randomized trials that included patients receiving neoadjuvant/concurrent or concurre …
Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade.
Masiá M, Fernández-González M, García JA, Padilla S, García-Abellán J, Botella Á, Mascarell P, Agulló V, Gutiérrez F. Masiá M, et al. Among authors: garcia ja. EBioMedicine. 2022 Aug;82:104153. doi: 10.1016/j.ebiom.2022.104153. Epub 2022 Jul 8. EBioMedicine. 2022. PMID: 35816896 Free PMC article.
We aimed to investigate the effects of IL-6 blockade on long-term immunity to SARS-CoV-2. METHODS: Prospective, longitudinal cohort study conducted in patients hospitalized for severe or critical COVID-19 with laboratory confirmed SARS-CoV-2 infection. ...INTERPRETATION: I …
We aimed to investigate the effects of IL-6 blockade on long-term immunity to SARS-CoV-2. METHODS: Prospective, longitudinal cohort s …
Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study.
Torres A, Motos A, Cillóniz C, Ceccato A, Fernández-Barat L, Gabarrús A, Bermejo-Martin J, Ferrer R, Riera J, Pérez-Arnal R, García-Gasulla D, Peñuelas O, Lorente JÁ, de Gonzalo-Calvo D, Almansa R, Menéndez R, Palomeque A, Villar RA, Añón JM, Balan Mariño A, Barberà C, Barberán J, Blandino Ortiz A, Boado MV, Bustamante-Munguira E, Caballero J, Cantón-Bulnes ML, Carbajales Pérez C, Carbonell N, Catalán-González M, de Frutos R, Franco N, Galbán C, Gumucio-Sanguino VD, de la Torre MDC, Díaz E, Estella Á, Gallego E, García Garmendia JL, Gómez JM, Huerta A, García RNJ, Loza-Vázquez A, Marin-Corral J, Martin Delgado MC, Martínez de la Gándara A, Martínez Varela I, López Messa J, Albaiceta GM, Nieto M, Novo MA, Peñasco Y, Pérez-García F, Pozo-Laderas JC, Ricart P, Sagredo V, Sánchez-Miralles A, Sancho Chinesta S, Serra-Fortuny M, Socias L, Solé-Violan J, Suarez-Sipmann F, Tamayo Lomas L, Trenado J, Úbeda A, Valdivia LJ, Vidal P, Barbé F; CIBERESUCICOVID Project Investigators. Torres A, et al. Intensive Care Med. 2022 Jul;48(7):850-864. doi: 10.1007/s00134-022-06726-w. Epub 2022 Jun 21. Intensive Care Med. 2022. PMID: 35727348 Free PMC article.
Significant effect modification was found after adjustment for covariates using propensity score for age (p = 0.001 interaction term), Sequential Organ Failure Assessment (SOFA) score (p = 0.014 interaction term), and mechanical ventilation (p = 0.001 interaction …
Significant effect modification was found after adjustment for covariates using propensity score for age (p = 0.001 interaction term) …
High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.
Kishan AU, Wang X, Sun Y, Romero T, Michalski JM, Ma TM, Feng FY, Sandler HM, Bolla M, Maingon P, De Reijke T, Neven A, Steigler A, Denham JW, Joseph D, Nabid A, Carrier N, Souhami L, Sydes MR, Dearnaley DP, Syndikus I, Tree AC, Incrocci L, Heemsbergen WD, Pos FJ, Zapatero A, Efstathiou JA, Guerrero A, Alvarez A, San-Segundo CG, Maldonado X, Xiang M, Rettig MB, Reiter RE, Zaorsky NG, Ong WL, Dess RT, Steinberg ML, Nickols NG, Roy S, Garcia JA, Spratt DE; MARCAP Consortium. Kishan AU, et al. Among authors: garcia ja. Eur Urol. 2022 Jul;82(1):106-114. doi: 10.1016/j.eururo.2022.04.003. Epub 2022 Apr 22. Eur Urol. 2022. PMID: 35469702
BACKGROUND: The relative benefits of radiotherapy (RT) dose escalation and the addition of short-term or long-term androgen deprivation therapy (STADT or LTADT) in the treatment of prostate cancer are unknown. ...According to P-score ranking and rankogram analysis, …
BACKGROUND: The relative benefits of radiotherapy (RT) dose escalation and the addition of short-term or long-term androgen de …
Clinical Performance of a Standardized Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Interferon-γ Release Assay for Simple Detection of T-Cell Responses After Infection or Vaccination.
Fernández-González M, Agulló V, Padilla S, García JA, García-Abellán J, Botella Á, Mascarell P, Ruiz-García M, Masiá M, Gutiérrez F. Fernández-González M, et al. Among authors: garcia ja. Clin Infect Dis. 2022 Aug 24;75(1):e338-e346. doi: 10.1093/cid/ciab1021. Clin Infect Dis. 2022. PMID: 34893816 Free PMC article.
The greatest contribution of IGRA to serological tests was observed in patients with mild disease and long-term FU (incremental difference, 30.4%). CONCLUSIONS: The IGRA was a reliable method of quantifying T-cell response after SARS-COV-2 infection or vaccination. ...
The greatest contribution of IGRA to serological tests was observed in patients with mild disease and long-term FU (incremental diffe …
Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study.
García-Abellán J, Padilla S, Fernández-González M, García JA, Agulló V, Andreo M, Ruiz S, Galiana A, Gutiérrez F, Masiá M. García-Abellán J, et al. Among authors: garcia ja. J Clin Immunol. 2021 Oct;41(7):1490-1501. doi: 10.1007/s10875-021-01083-7. Epub 2021 Jul 17. J Clin Immunol. 2021. PMID: 34273064 Free PMC article.
BACKGROUND: The relationship of host immune response and viral replication with health outcomes in patients with COVID-19 remains to be defined. We aimed to characterize the medium and long-term clinical, virological, and serological outcomes after hospitalization for COVI …
BACKGROUND: The relationship of host immune response and viral replication with health outcomes in patients with COVID-19 remains to be defi …
55 results